Navigation Links
Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22
Date:1/13/2009

BOSTON, Jan. 13 /PRNewswire/ -- Responding to the increased risk to patient safety in an economic downturn, the National Patient Safety Foundation has announced that the 2009 NPSF Patient Safety Congress will directly address this issue through an extensive program of educational sessions designed to provide attendees with the new thinking and tools critical to keeping patients safe.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO)

This highly acclaimed annual event, to be held May 20-22 at the Gaylord National outside Washington, DC, boasts over 35 individual sessions targeting seven core areas essential to patient safety. In addition, insightful and inspiring plenaries are planned, including a town hall meeting with authors of the pivotal Institute of Medicine report "To Err Is Human" and distinguished members of the Lucian Leape Institute. Intensive full-day pre-Congress programs will also be offered, highlighted by a unique executive-level event providing case studies and discussion focused on successfully building a safety framework, setting safety and quality priorities, and ensuring critical physician engagement. Plus, the NPSF Congress provides direct access to a wide array of innovative solutions providers.

"These times demand increased vigilance from us all," explained Diane Pinakiewicz, President of the National Patient Safety Foundation, "and, as adversity threatens, it also sparks creativity and unique problem-solving, a mindset that is at the very heart of this year's Congress."

Widely recognized as the definitive patient safety event each year, the 2009 NPSF Congress will provide the new learnings, practical tools, and innovative solutions essential to keeping patients safe during these challenging times, and will offer unparalleled opportunities for attendees to
'/>"/>

SOURCE National Patient Safety Foundation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
7. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
8. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
9. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
10. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
11. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 19, 2011 , , • ... MS drug with neuroprotective effects that does not cause,immunosuppression. ... the first,to be administered orally, whereas the few treatments ... significant side effects. • NeuroAdvan, the ...
... Mosquitoes die soon after a blood meal if certain ... at the University of Arizona has discovered. The ... the worldwide effort to curb mosquito-borne diseases like dengue ... blocked a cellular process known as vesicle transport, on ...
... dots made from cadmium and selenium degrade in soil, ... a University at Buffalo study has found. The ... Science and Technology , demonstrates the importance of learning ... -- interact with the environment after disposal, said Diana ...
Cached Biology Technology:Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 2Cadmium selenide quantum dots degrade in soil, releasing their toxic guts, study finds 3
(Date:4/15/2014)... fuel cell systems soon could be powering the forklifts ... costs and with faster refueling times than ever before, ... Hawaii Hydrogen Carriers (HHC). , The goal of the ... that can refuel at low pressure four to five ... forklift, giving hydrogen a competitive advantage over batteries for ...
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2
... birthday, according to new infant mortality statistics for 2003 ... , The infant mortality rates showed no significant improvement ... time since 1958. , In 2003, the infant ... births, which was statistically unchanged from the 2002 rate ...
... more trick to the amazing repertoire of carbon nanotubes ... cells. , Nanotubes, tiny hollow carbon filaments about one ... famed as one of the most versatile materials ever ... one-sixth as dense, able to conduct electricity better than ...
... mouse or a rat under stress and what does ... lucky. When people suffer nontraumatic stress they often head ... Syrian hamsters, which are normally solitary, are placed in ... at the Center for Behavioral Neuroscience at Georgia State ...
Cached Biology News:US infant mortality rate fails to improve 2Nanotubes used for first time to send signals to nerve cells 2Just like us, social stress prompts hamsters to overeat, gain weight 2Just like us, social stress prompts hamsters to overeat, gain weight 3Just like us, social stress prompts hamsters to overeat, gain weight 4
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
... 2 (VMAT2). An antibody made to the ... at ~55 kDa in postnuclear supernatants of ... wild type cells (2). Some additional bands, ... also detected and remain unaffected by the ...
... Anti-Matrix Metalloproteinase-2, Hinge Region By immunoblotting ... native protein. It reacts with free MMP-2 ... antibody buffered aqueous glycerol solution ... pH 7.4, containing 50% glycerol and 15 ...
Acetylcholinesterase from human and monkey....
Biology Products: